NCT07158489
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT07158489 |
| Title | Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC (ORIGIN2) |
| Acronym | ORIGIN2 |
| Recruitment | Not yet recruiting |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Swiss Cancer Institute |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | CHE |
CKB BOOST